# TASK ORDER 07 (75N95022F00001) FOR IDIQ HHSN271201800024I WITH EUROFINS PANLABS DISCOVERY SERVICES

> **NIH NIH N01** · EUROFINS PANLABS, INC. · 2022 · $224,328

## Abstract

The objective of this acquisition is to continue a major component of the National Institute on Drug Abuse’s (NIDA) established contracts, the NIDA/Division of Therapeutics and Medical Consequences (DTMC)/Addiction Treatment Discovery Program (ATDP). The program requires in-house capability to perform in vitro receptor binding assays on a wide variety of receptor targets, and perform follow-up binding and functional assays using appropriate in vitro biological systems, in addition to in vitro predictive toxicology assays.

## Key facts

- **NIH application ID:** 10721002
- **Project number:** 271201800024I-0-759502200001-1
- **Recipient organization:** EUROFINS PANLABS, INC.
- **Principal Investigator:** JACOB BODE
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $224,328
- **Award type:** —
- **Project period:** 2018-09-21 → 2023-09-20

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10721002

## Citation

> US National Institutes of Health, RePORTER application 10721002, TASK ORDER 07 (75N95022F00001) FOR IDIQ HHSN271201800024I WITH EUROFINS PANLABS DISCOVERY SERVICES (271201800024I-0-759502200001-1). Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/grant/nih/10721002. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*